Search

Displaying results 1861 - 1870 of 4539 in total
  1. Drug

    Etorphine

    go.drugbank.com/drugs/DB01497
    ExperimentalIllicitVet approved

    In the US, Etorphine is listed as a Schedule I drug, although Etorphine hydrochloride is classified as Schedule II. … In certain countries, etorphine is classified as a Schedule 1 drug and hence, in these countries, it can be used legally only by health professionals and for research purposes.

  2. Drug

    Arsenic trioxide

    go.drugbank.com/drugs/DB01169
    ApprovedInvestigational

    Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic ...

  3. Drug

    Pramlintide

    go.drugbank.com/drugs/DB01278
    ApprovedInvestigational

    Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals.

  4. Drug

    Gimeracil

    go.drugbank.com/drugs/DB09257
    ApprovedInvestigational

    It functions by reversibly and selectively blocking the enzyme dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU [A31408]. … Approved by the European Medicines Agency (EMA) in March 2011, Gimeracil is available in combination with [DB03209] and [DB09256] within the commercially available product "Teysuno".

  5. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    to be approved by the FDA. … [A244815] On January 26, 2022, tebentafusp was first approved by the FDA for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.

  6. Drug

    Rifapentine

    go.drugbank.com/drugs/DB01201
    ApprovedInvestigational

    Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.

  7. Drug

    Busulfan

    go.drugbank.com/drugs/DB01008
    ApprovedInvestigational

    It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about.

  8. Drug

    Digoxin

    go.drugbank.com/drugs/DB00390
    ApprovedInvestigational

    [A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. … [L9143] This drug originates from the foxglove plant, also known as the _Digitalis_ plant[T610], studied by William Withering, an English physician and botanist in the 1780s.

  9. Drug

    Dextrothyroxine

    go.drugbank.com/drugs/DB00509
    ApprovedWithdrawn

    Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood.

  10. Drug

    Potassium cation

    go.drugbank.com/drugs/DB01345
    Approved

    The balance between potassium and sodium is maintained by ion pumps in the cell membrane. … The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge.